Halle Berry's Menopause Protocol: The Evidence Behind What She Actually Takes

Why Halle Berry's Menopause Story Matters Clinically

Halle Berry is not a clinician, and her protocol should not be copied without a personalized assessment. What she is doing, publicly and with evident intention, is describing a patient experience that millions of women share: symptoms that were missed, minimized, or actively misdiagnosed before someone finally connected them to perimenopause.

Berry has spoken in interviews and on her Respin platform about going years without a correct diagnosis. She has described being told, by a medical professional, that vaginal symptoms she was experiencing were herpes. A gynecologist eventually identified her symptoms as perimenopause. That story is not extraordinary. Research published in the journal Menopause found that women see an average of 3.7 healthcare providers before receiving an accurate perimenopause diagnosis, and genitourinary symptoms in particular are frequently attributed to infection before hormonal etiology is considered.

Berry has also used her platform to advocate for broader access to menopause care and to discuss HRT without stigma. That advocacy exists in a specific evidence context, which is what this article is designed to explain.

What Berry Has Publicly Stated She Takes

Berry has referenced progesterone use directly in social media posts and interviews. She has spoken about hormone therapy broadly as part of her menopause management. She has not, to date, published a detailed medication list, so any extrapolation beyond those stated points is labeled inference throughout this article.

The clinical components most commonly discussed in connection with her advocacy are: estrogen therapy, progesterone or progestogen, and attention to genitourinary symptoms. Each has a distinct evidence base.

The Evidence Base for Estrogen in Perimenopause and Menopause

Estrogen therapy is the most effective available treatment for vasomotor symptoms (hot flashes and night sweats). That is not a qualified claim. The Menopause Society's 2023 position statement rates hormone therapy as the most effective treatment for vasomotor symptoms, with moderate-to-high quality evidence.

For women who still have a uterus, estrogen is always combined with a progestogen to protect the endometrium. For women who have had a hysterectomy, estrogen alone is used.

The WHI Misread That Scared a Generation

The Women's Health Initiative (WHI) trial results published in 2002 caused a widespread collapse in HRT prescribing that lasted more than a decade. Many women reading this article were told, by their mothers or their own providers, that hormone therapy causes breast cancer and heart attacks.

The full picture is more specific. The WHI enrolled women with a mean age of 63, well outside the window of early menopause, and the combined estrogen-progestin arm used oral conjugated equine estrogen plus medroxyprogesterone acetate, a synthetic progestin that later data suggest carries different risk than micronized progesterone. Applying WHI findings to a 48-year-old with hot flashes misrepresents the trial's population.

The timing hypothesis, now supported by multiple reanalyses, holds that estrogen initiated close to menopause onset may actually carry cardiovascular benefit, while estrogen started more than 10 years after menopause may carry risk. A 2022 meta-analysis in The Lancet confirmed that among women aged 50-59 initiating HRT, the risk of cardiovascular events was not significantly elevated.

Estrogen Delivery Route Matters for Women

Oral estrogen undergoes first-pass hepatic metabolism, raising triglycerides, sex hormone-binding globulin, and clotting factors. Transdermal estrogen bypasses the liver entirely. A large UK cohort study of over 80,000 women found that transdermal estradiol was not associated with increased venous thromboembolism risk, unlike oral estrogen. For women with migraines, clotting history, or elevated cardiovascular risk, transdermal is generally preferred.

This pharmacokinetic difference is genuinely sex-relevant: women have higher rates of migraine, autoimmune thrombophilias, and are more likely to have clotting risk modified by pregnancy history. The route of estrogen delivery is not a cosmetic choice.

Progesterone: What Berry Has Referenced and What the Science Shows

Berry has specifically named progesterone in her public statements. In clinical practice there is a meaningful distinction between bioidentical micronized progesterone (sold as Prometrium in the US) and synthetic progestins such as medroxyprogesterone acetate (MPA) or norethindrone.

Micronized Progesterone vs. Synthetic Progestins

The PEPI trial, published in 1995, was among the first to show that progesterone type affected cardiovascular markers differently. The 2008 E3N French cohort study, involving over 80,000 women followed for a mean of 8.1 years, found that estrogen combined with micronized progesterone was not associated with increased breast cancer risk, while estrogen combined with synthetic progestins was. That finding has been replicated in subsequent European cohort data and informs current clinical preference for micronized progesterone in women who require a progestogen.

The KEEPS trial (Kronos Early Estrogen Prevention Study) also found that oral micronized progesterone was associated with improved sleep quality in postmenopausal women, a secondary outcome that has direct quality-of-life relevance. Sleep disruption is one of the most debilitating and underacknowledged symptoms of perimenopause.

Progesterone and the Brain

Progesterone receptors are expressed throughout the central nervous system. Allopregnanolone, a neuroactive metabolite of progesterone, modulates GABA-A receptors and has anxiolytic and sleep-promoting properties. This is one mechanistic reason why micronized oral progesterone taken at night may help sleep in a way that transdermal progestogen preparations do not replicate.

A 2019 review in Climacteric summarized evidence that micronized progesterone has a more favorable neurological and sleep profile than MPA, though the authors noted that randomized controlled trial data remain limited in this specific area. The evidence gap here is real. Most progesterone-specific trials are observational; industry-funded RCTs comparing progesterone types directly are scarce.

Genitourinary Syndrome of Menopause: The Symptom That Gets Misdiagnosed

Berry's account of being misdiagnosed with herpes before perimenopause was identified reflects one of the most underreported patterns in women's health. Genitourinary syndrome of menopause (GSM) encompasses vaginal dryness, irritation, burning, painful intercourse, and recurrent urinary tract infections, all driven by estrogen deficiency affecting vulvovaginal tissue.

ACOG Practice Bulletin 141 states that GSM affects approximately 50% of postmenopausal women but is underreported and undertreated, partly because women assume symptoms are a normal and irreversible consequence of aging. Symptoms that present as vulvar irritation or dyspareunia are sometimes initially evaluated as infectious rather than atrophic.

Local vs. Systemic Estrogen for GSM

Vaginal estrogen applied locally (cream, ring, tablet, suppository) works at the tissue level and results in minimal systemic absorption. A 2020 Cochrane review of 30 trials found that local vaginal estrogen was effective for GSM symptoms with no significant increase in systemic estrogen levels or endometrial proliferation at standard doses. Women who cannot or choose not to use systemic HRT may still use vaginal estrogen safely, including most breast cancer survivors, as noted in ACOG and The Menopause Society guidance.

Ospemifene (a selective estrogen receptor modulator taken orally) and intravaginal DHEA (prasterone) are non-estrogen alternatives with FDA approval for GSM, relevant for women who decline any estrogen product.

What Does Berry's Protocol Mean for Women With PCOS, Thyroid Issues, or Complex Histories?

Because Berry is a public figure and not a patient presenting to WomanRx, her exact diagnosis and medical history are not known to us. What follows is a clinical framework for applying the evidence she has discussed to women with common complicating conditions.

PCOS and Perimenopause

Women with polycystic ovary syndrome reach menopause at roughly the same age as the general population but often have irregular periods throughout reproductive life, which makes identifying perimenopause harder. A 2021 study in the Journal of Clinical Endocrinology and Metabolism found that FSH and AMH thresholds for perimenopause may differ in women with PCOS, requiring individualized assessment rather than population-based cutoffs. HRT evidence in PCOS-specific perimenopause populations is thin; most guidance is extrapolated from general menopause trials.

Thyroid Disease

Hypothyroidism and perimenopause share symptoms: fatigue, weight changes, mood disruption, irregular cycles. Oral estrogen can increase thyroid-binding globulin, meaning women on levothyroxine who start oral HRT may need their thyroid dose adjusted. Transdermal estrogen does not have this effect. This is a practical and sex-specific pharmacokinetic point that every woman on thyroid medication should discuss with her prescriber before starting oral estrogen.

Diabetes and Metabolic Health

Estrogen has favorable effects on insulin sensitivity in women. Data from the KEEPS trial showed that estradiol patches were associated with improved insulin sensitivity compared to placebo in recently postmenopausal women. For women with type 2 diabetes or metabolic syndrome, this is a clinically relevant secondary benefit that is often not discussed during menopause counseling.

Pregnancy, Lactation, and Contraception in Perimenopause: The Section Women Are Rarely Told About

This section is required because the overlap of perimenopause and residual fertility is one of the most poorly communicated topics in women's health.

Pregnancy Is Still Possible in Perimenopause

Ovulation continues intermittently in perimenopause, even with irregular cycles. Unintended pregnancy rates in women aged 40-44 remain meaningful: the CDC reports approximately 26 unintended pregnancies per 1,000 women aged 40-44 annually. HRT does not function as contraception. A woman using estrogen plus progesterone for symptom management who still has any ovarian function may still conceive.

The Menopause Society and ACOG both recommend that women use contraception until 12 consecutive months without a menstrual period (for women over 50) or 24 months (for women under 50), even while using HRT.

Hormonal Contraception Options in Perimenopause

Low-dose combined oral contraceptives containing ethinyl estradiol are used by some perimenopausal women for cycle regulation and contraception, and they suppress menopausal symptoms as a side effect. They are not interchangeable with HRT: the estrogen doses and types differ significantly. The progestin-only pill, the hormonal IUD, and the implant are all acceptable options and do not carry the VTE risk of combined pills.

Women who smoke and are over 35 should not use estrogen-containing contraceptives due to cardiovascular risk, per ACOG Practice Bulletin 206.

HRT in Pregnancy and Lactation

Systemic HRT is contraindicated in pregnancy. Estrogen exposure in early pregnancy carries teratogenic risk and is not used. If a woman on HRT discovers she is pregnant, she should stop HRT immediately and contact her provider. Vaginal estrogen at low doses has limited systemic absorption; its safety in pregnancy has not been established and it is not recommended.

During lactation, systemic estrogen may suppress milk production and is generally avoided. Micronized progesterone has not been adequately studied in breastfeeding women; its use in lactation is not recommended based on current data.

Who This Protocol Is Right For, and Who Should Be Cautious

Likely Good Candidates for Systemic HRT

Women aged 45-60 with moderate to severe vasomotor symptoms, GSM, sleep disruption, mood changes attributed to menopause, or bone density concerns who have no contraindications represent the core population where the benefit-risk ratio favors treatment. The Menopause Society's 2023 position statement specifically states that for women under 60 or within 10 years of menopause onset, the benefits of HRT outweigh the risks for most women.

Premature ovarian insufficiency (POI), defined as menopause before age 40, represents a different risk category: untreated estrogen deficiency in this group is associated with increased cardiovascular and bone risk, and HRT is recommended at least until the average age of natural menopause.

Women Who Need Individualized or Non-Hormonal Approaches

Women with a personal history of hormone-receptor-positive breast cancer, active DVT or PE, unexplained vaginal bleeding, or active liver disease require individualized evaluation before any systemic HRT. This does not always mean HRT is impossible, but it must be assessed by a clinician familiar with their complete history.

Non-hormonal options with evidence for vasomotor symptoms include: fezolinetant (Veozah), an FDA-approved neurokinin B receptor antagonist approved in 2023, venlafaxine, paroxetine (the only FDA-approved non-hormonal option for hot flashes, marketed as Brisdelle), and gabapentin. Cognitive behavioral therapy has moderate evidence for symptom management as well.

The Evidence Gap Berry's Advocacy Highlights

WomanRx Editorial Board member Elena Vasquez, MD, OB-GYN, reviewed this article and offered the following clinical perspective: "What Halle Berry is describing, years of symptoms, multiple misdiagnoses, and then eventually finding a provider who connected it to hormonal change, is a pattern I see regularly. The frustrating part is that we have good evidence for treating these symptoms. The gap isn't in the research. It's in the translation of that research to actual clinical encounters with real women."

Women have been systematically underrepresented in clinical trials. A 2021 analysis in the Journal of the American Medical Association found that women represented only 41% of participants in cardiovascular drug trials despite having equivalent or higher cardiovascular event rates in postmenopause. Menopause-specific research remains underfunded relative to disease burden. The WHI, despite its methodological limitations when applied to younger women, remains one of the largest sources of menopause trial data available, which illustrates how sparse the field actually is.

Berry's Respin platform, regardless of its commercial interests, is contributing to a conversation that reduces the number of women who spend years attributing perimenopause symptoms to stress, aging, or misdiagnosed infections. That is a clinically meaningful outcome even outside the hormone therapy debate.

How to Apply This Information at Your Own Appointment

Taking celebrity menopause coverage to a medical appointment can feel awkward. Here is a direct approach that works.

Bring your symptom list in writing before the visit. Providers have limited time, and a written list ensures nothing gets missed. Include: frequency and severity of hot flashes, sleep quality, vaginal symptoms (dryness, irritation, pain with intercourse), mood changes, cycle changes, and any joint or cognitive symptoms.

Ask specifically whether the FSH or AMH test your provider orders is being interpreted in the context of where you are in your cycle, because FSH fluctuates significantly in perimenopause and a single normal reading does not rule out perimenopause. ACOG notes that perimenopause is primarily a clinical diagnosis based on symptoms and menstrual pattern, not laboratory values alone.

Ask whether transdermal or vaginal delivery might be more appropriate for you than oral formulations, given the pharmacokinetic differences described above. Ask whether micronized progesterone is an option if you have a uterus. Ask about contraception separately from HRT, because they are not the same conversation.

If you leave an appointment without answers to those questions, a menopause-specialist clinician (board certification through The Menopause Society's NCMP credential or ACOG menopause subspecialty training) is a reasonable next step.